Myeloperoxidase-antineutrophil cytoplasmic antibody-associated diffuse alveolar hemorrhage caused by denosumab
Issued Date
2022-01-01
Resource Type
eISSN
22130071
Scopus ID
2-s2.0-85133423928
Journal Title
Respiratory Medicine Case Reports
Volume
38
Rights Holder(s)
SCOPUS
Bibliographic Citation
Respiratory Medicine Case Reports Vol.38 (2022)
Suggested Citation
Kasemchaiyanun A. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated diffuse alveolar hemorrhage caused by denosumab. Respiratory Medicine Case Reports Vol.38 (2022). doi:10.1016/j.rmcr.2022.101690 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87421
Title
Myeloperoxidase-antineutrophil cytoplasmic antibody-associated diffuse alveolar hemorrhage caused by denosumab
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Denosumab is a bone anti-resorptive drug, commonly used for treating osteoporosis. Pulmonary involvement has rarely been reported as a possible serious adverse effect of this medication. Herein, we report the case of a 67-year-old woman who presented with non-massive hemoptysis, anemia, and extensive pulmonary opacities on a chest radiograph for 3 days after receiving denosumab. The patient was diagnosed with myeloperoxidase-antineutrophil cytoplasmic antibody-associated pulmonary hemorrhage secondary from denosumab. She was treated with high doses of intravenous methylprednisolone and cyclophosphamide combined with plasmapheresis. Subsequently, her clinical and radiological findings improved without residual abnormalities after treatment.